中国罕见病药品专利现状分析——基于2-模网络分析视角  

Analysis on the patent of rare diseases in China: based on a two-mode network perspective

作　　者：李树祥[1] 褚淑贞[1] 杨庆[1] LI Shu-xiang;CHU Shu-zhen;YANG Qing(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学国际医药商学院,南京211198

出　　处：《中国新药杂志》2022年第7期617-623,共7页Chinese Journal of New Drugs

基　　金：江苏高校哲学社会科学项目(2020SJA0086);江苏省软科学项目(BR2020040);中国药科大学商学院力凡胶囊青年教师基金(LFJJ-08)。

摘　　要：罕见病因为发病率低、治疗复杂、缺乏针对性治疗药品,治疗药品的研发成为医药产业亟待解决的问题。我国最近几年在罕见病诊疗方面已经有了极大的进步,但是在药品研发方面和发达国家相比还存在一定的差距。本研究利用社会网络分析方法对中国罕见病药品研发专利现状进行分析。研究结果显示当前我国罕见病药品研发仍然较为滞后,药品专利更多集中于国外药品研发企业。为了推动罕见病药品研发,国家需要给出进一步的激励政策,同时罕见病药品研发中的产-学-研合作机制也有待进一步完善。Rare diseases have become an urgent unresolved problem in modern pharmaceutical industry due to the low incidence, complex treatment, and lack of targeted therapeutic drugs. In recent years, China has made great progress in the treatment of rare diseases;however, a certain gap still exists in the aspect of drug research and development compared with foreign countries. This study applies social network to analyze the current status of China’s patents regarding rare disease drug research and development. The results of this study show that the current research and development of drugs against rare disease in China still lag behind, and the drug patents are highly concentrated in drug research and development companies outside China. In order to promote the research and development of rare disease drugs, further incentive policies should be provided in national range, and at the same time, the industry-academy cooperation mechanism in research and development of such drugs also needs to be further improved.

关 键 词：罕见病 药品 专利 2-模网 

分 类 号：R95[医药卫生—药学]